Page 887 - Basic _ Clinical Pharmacology ( PDFDrive )

See footnote 4. Avoid darunavir, garlic capsules, tipranavir and drugs that increase the QT interval. Avoid in severe hepatic insufficiency. Avoid zidovudine and neuropathic drugs (eg, ddI, zalcitabine, isoniazid). Avoid inducers of p-glycoprotein (rifampin, rifabutin, phenytoin, phenobarbital, St John’s Wort, tipranavir/ ritonavir). Also avoid in severe renal insufficiency. Avoid atazanavir, didanosine, probenecid. See footnote 4. Avoid concurrent ata- zanavir, elvitegravir/cobicistat, etravirine, fosam

Nausea, diarrhea, abdominal pain, dyspepsia, rash Peripheral neuropathy, pan- creatitis, rapidly progressive ascending neuromuscular weakness (rare) Gastrointestinal symptoms, headache, ↑ creatinine, proteinuria Nausea, diarrhea, vomiting, flatulence, headache, renal insufficiency Diarrhea, nausea, vomiting, abdominal pain, rash, ↑ liver enzymes, hyperlipidemia Macrocytic anemia, neutro- penia, nausea, headache, insomnia, myopathy

Take within 2 h of a full meal. Take with food. Separate from ddI by ≥2 h. Avoid antacids. 4 Because of altered systemic exposures, concurrent drugs that interact with the CYP3A4 system should be used with caution, including alfuzosin, amiodarone, aprepitant, artemether/lumefantrine, astemizole, atovaquone, benzodi- azepines (diazepam, midazolam, triazolam), bexarotene, bepridil, bosentan, bupropion, calcium channel blockers (diltiazem, felodipine, nifedipine, nimodipine, verapamil), carbamazepine, c

1000 mg bid with ritonavir 100 mg bid 30–40 mg bid, depending on weight 3 10 mg qd with emtricitabine plus elvitegravir/cobicistat; 25 mg qd with emtricitabine ± rilpivirine 300 mg qd 3 500 mg bid with ritonavir 200 mg bid 200 mg tid or 300 mg bid 3 2 All PI agents carry the risk of hyperlipidemia, fat maldistribution, hyperglycemia, and insulin resistance as potential adverse events. INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide

NRTI 1 NRTI 1 NRTI 1 NRTI 1 1 All NRTI agents carry the risk of lactic acidosis with hepatic steatosis as a potential adverse event. conazole ketoconazole, posaconazole, voriconazole), terfenadine, and warfarin.
PI 2 PI 2 3 Adjust dose in renal insufficiency.

Rilpivirine Stavudine Tenofovir alafenamide Tenofovir diso- proxil fumarate Tipranavir Zidovudine

873